H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on X4 Pharmaceuticals to $5 from $3.50 and keeps a Buy rating on the shares. The company announced positive top-line data from the Phase 3 randomized, placebo-controlled, 4WHIM study, Ramakanth tells investors in a research note. The anlayst is encouraged by the positive top-line data and increased the launch probability of mavorixafor as a treatment for WHIM syndrome to 60% from 48.5%.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on XFOR:
- X4 Pharmaceuticals announces 4WHIM trial meets primary endpoint
- X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022